{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:52:04Z","timestamp":1781923924583,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"DOI":"10.7759\/cureus.111175","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:35:26Z","timestamp":1781922926000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic and Clinicopathological Utility of High-Molecular-Weight Cytokeratin (HMWCK) and NKX3.1 Immunohistochemistry in Prostatic Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Ayushi","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenat S","family":"Imam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford P","year":"2024","unstructured":"Cornford P, van den Bergh RC, Briers E, et al.. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024, 86:148-63. 10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800054","article-title":"Gleason grading and prognostic factors in carcinoma of the prostate","volume":"17","author":"Humphrey PA","year":"2004","unstructured":"Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004, 17:292-306. 10.1038\/modpathol.3800054","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11611.x","article-title":"Prognostic Gleason grade grouping: data based on the modified Gleason scoring system","volume":"111","author":"Pierorazio PM","year":"2013","unstructured":"Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013, 111:753-60. 10.1111\/j.1464-410X.2012.11611.x","journal-title":"BJU Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2023.10.005","article-title":"Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients","volume":"56","author":"Samaratunga H","year":"2024","unstructured":"Samaratunga H, Egevad L, Yaxley J, et al.. Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients. Pathology. 2024, 56:33-8. 10.1016\/j.pathol.2023.10.005","journal-title":"Pathology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000238","article-title":"Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Epstein JI","year":"2014","unstructured":"Epstein JI, Egevad L, Humphrey PA, Montironi R. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014, 38:e6-e19. 10.1097\/PAS.0000000000000238","journal-title":"Am J Surg Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200209000-00005","article-title":"Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody","volume":"26","author":"Oliai BR","year":"2002","unstructured":"Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol. 2002, 26:1151-60. 10.1097\/00000478-200209000-00005","journal-title":"Am J Surg Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.30699\/ijp.2020.113544.2229","article-title":"Diagnostic value of cytokeratin 34 beta E12 (Ck34\u03b2E12) and \u03b1-methylacyl-CoA racemase (AMACR) immunohistochemical expression in prostatic lesions","volume":"15","author":"Hasan IA","year":"2020","unstructured":"Hasan IA, Gaidan HA, Al-Kaabi MM. Diagnostic value of cytokeratin 34 beta E12 (Ck34\u03b2E12) and \u03b1-methylacyl-CoA racemase (AMACR) immunohistochemical expression in prostatic lesions. Iran J Pathol. 2020, 15:232-8. 10.30699\/ijp.2020.113544.2229","journal-title":"Iran J Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31802f5d33","article-title":"Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma","volume":"31","author":"Chuang AY","year":"2007","unstructured":"Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007, 31:1246-55. 10.1097\/PAS.0b013e31802f5d33","journal-title":"Am J Surg Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2005.11.007","article-title":"Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features","volume":"202","author":"Aslan G","year":"2006","unstructured":"Aslan G, Irer B, Tuna B, Yorukoglu K, Saatcioglu F, Celebi I. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract. 2006, 202:93-8. 10.1016\/j.prp.2005.11.007","journal-title":"Pathol Res Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0963","article-title":"Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion","volume":"66","author":"Bethel CR","year":"2006","unstructured":"Bethel CR, Faith D, Li X, et al.. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 2006, 66:10683-90. 10.1158\/0008-5472.CAN-06-0963","journal-title":"Cancer Res"},{"key":"ref12","article-title":"Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression","volume":"60","author":"Bowen C","year":"2000","unstructured":"Bowen C, Bubendorf L, Voeller HJ, et al.. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000, 60:6111-5.","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-208073","article-title":"Gene of the month: NKX3.1","volume":"75","author":"Griffin J","year":"2022","unstructured":"Griffin J, Chen Y, Catto JW, El-Khamisy S. Gene of the month: NKX3.1. J Clin Pathol. 2022, 75:361-4. 10.1136\/jclinpath-2021-208073","journal-title":"J Clin Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10210","article-title":"Expression of NKX3.1 in normal and malignant tissues","volume":"55","author":"Gelmann EP","year":"2003","unstructured":"Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate. 2003, 55:111-7. 10.1002\/pros.10210","journal-title":"Prostate"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"Gurel B","year":"2010","unstructured":"Gurel B, Ali TZ, Montgomery EA, et al.. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010, 34:1097-105. 10.1097\/PAS.0b013e3181e6cbf3","journal-title":"Am J Surg Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqz063","article-title":"Utility of NKX3.1 immunostaining in the detection of metastatic prostatic carcinoma on fine-needle aspiration smears","volume":"152","author":"Gan Q","year":"2019","unstructured":"Gan Q, Joseph CT, Guo M, Zhang M, Sun X, Gong Y. Utility of NKX3.1 immunostaining in the detection of metastatic prostatic carcinoma on fine-needle aspiration smears. Am J Clin Pathol. 2019, 152:495-501. 10.1093\/ajcp\/aqz063","journal-title":"Am J Clin Pathol"},{"key":"ref17","article-title":"Expression of NKX3.1, prostatic specific antigen and prostatic specific alkaline phosphatase in cytology specimens of metastatic prostatic carcinoma","volume":"1","author":"Wang M","year":"2021","unstructured":"Wang M, Abi-Raad R, Adeniran AJ, Cai G. Expression of NKX3.1, prostatic specific antigen and prostatic specific alkaline phosphatase in cytology specimens of metastatic prostatic carcinoma. J Clin Transl Pathol. 2021, 1:16-20.","journal-title":"J Clin Transl Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1763359","article-title":"Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review)","volume":"16","author":"Rajaee Rizi F","year":"2026","unstructured":"Rajaee Rizi F, Jamadi MS, Rahimi S, Bighamian M, Paidar P, Taki MJ, Bahmaie N. Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review). Front Oncol. 2026, 16:1763359. 10.3389\/fonc.2026.1763359","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/111.2.223","article-title":"Perineural invasion in prostate needle biopsy specimens: correlation with extraprostatic extension at resection","volume":"111","author":"Vargas SO","year":"1999","unstructured":"Vargas SO, Jiroutek M, Welch WR, Nucci MR, D'Amico AV, Renshaw AA. Perineural invasion in prostate needle biopsy specimens: correlation with extraprostatic extension at resection. Am J Clin Pathol. 1999, 111:223-8. 10.1093\/ajcp\/111.2.223","journal-title":"Am J Clin Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.01.039","article-title":"Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer","volume":"68","author":"Lee IH","year":"2007","unstructured":"Lee IH, Roberts R, Shah RB, Wojno KJ, Wei JT, Sandler HM. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007, 68:1059-64. 10.1016\/j.ijrobp.2007.01.039","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002963","article-title":"Clinical significance of perineural invasion in men with Grade Group 1 prostate cancer on active surveillance","volume":"209","author":"de la Calle CM","year":"2023","unstructured":"de la Calle CM, Mamawala MM, Landis P, Macura KJ, Trock BJ, Epstein JI, Pavlovich CP. Clinical significance of perineural invasion in men with Grade Group 1 prostate cancer on active surveillance. J Urol. 2023, 209:180-6. 10.1097\/JU.0000000000002963","journal-title":"J Urol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24751","article-title":"Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: a comparative analysis of risk groups","volume":"84","author":"Ozkaya M","year":"2024","unstructured":"Ozkaya M, Simsekoglu MF, Kalender G, Sahin KC, Gurses I. Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: a comparative analysis of risk groups. Prostate. 2024, 84:1146-56. 10.1002\/pros.24751","journal-title":"Prostate"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213648","article-title":"The association between lymphovascular or perineural invasion in radical prostatectomy specimen and biochemical recurrence","volume":"16","author":"Siech C","year":"2024","unstructured":"Siech C, Wenzel M, Grosshans N, et al.. The association between lymphovascular or perineural invasion in radical prostatectomy specimen and biochemical recurrence. Cancers (Basel). 2024, 16:3648. 10.3390\/cancers16213648","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505791-diagnostic-and-clinicopathological-utility-of-high-molecular-weight-cytokeratin-hmwck-and-nkx31-immunohistochemistry-in-prostatic-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:35:27Z","timestamp":1781922927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505791-diagnostic-and-clinicopathological-utility-of-high-molecular-weight-cytokeratin-hmwck-and-nkx31-immunohistochemistry-in-prostatic-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.111175","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}